Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01443078 |
Recruitment Status :
Completed
First Posted : September 29, 2011
Results First Posted : August 9, 2016
Last Update Posted : August 9, 2018
|
Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Eli Lilly and Company
United States Department of Defense
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Condition |
Lung Cancer |
Interventions |
Drug: pemetrexed Drug: cisplatin Drug: Carboplatin Drug: Gemcitabine Hydrochloride Drug: Vinorelbine Tartrate Drug: Docetaxel |
Enrollment | 42 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | All Patients |
---|---|
![]() |
Patients with clinical Stage IB-III resectable and operable non-small cell lung cancer |
Period Title: Overall Study | |
Started | 42 |
Completed | 13 |
Not Completed | 29 |
Reason Not Completed | |
Responded to neoadjuvant platinum txt | 27 |
Withdrawal by Subject | 1 |
Patient had brain mets | 1 |
Baseline Characteristics
Arm/Group Title | All Patients | |
---|---|---|
![]() |
Patients with clinical Stage IB-III resectable and operable non-small cell lung cancer | |
Overall Number of Baseline Participants | 42 | |
![]() |
[Not Specified]
|
|
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 42 participants | |
<=18 years |
0 0.0%
|
|
Between 18 and 65 years |
22 52.4%
|
|
>=65 years |
20 47.6%
|
|
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 42 participants | |
Female |
27 64.3%
|
|
Male |
15 35.7%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Chaft, Jamie, MD |
Organization: | Memorial Sloan Kettering Cancer Center |
Phone: | 646-888-4545 |
EMail: | ChaftJ@mskcc.org |
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT01443078 |
Other Study ID Numbers: |
11-106 |
First Submitted: | September 26, 2011 |
First Posted: | September 29, 2011 |
Results First Submitted: | June 29, 2016 |
Results First Posted: | August 9, 2016 |
Last Update Posted: | August 9, 2018 |